The IBS-specific IgG ELISA-based elimination diet is a personalized dietary intervention designed to address food sensitivities in individuals with irritable bowel syndrome (IBS). This approach leverages an IgG antibody assay to identify specific food triggers that may contribute to IBS symptoms, such as abdominal pain, bloating, and altered bowel habits.
The IBS-specific IgG ELISA-based elimination diet is a personalized dietary intervention designed to address food sensitivities in individuals with irritable bowel syndrome (IBS). This approach leverages an IgG antibody assay to identify specific food triggers that may contribute to IBS symptoms, such as abdominal pain, bloating, and altered bowel habits. The study evaluating this diet aimed to improve upon methodological flaws seen in earlier IgG-related dietary research.
In a randomized, double-blind, sham-controlled multicenter trial conducted across 8 centers, adults with IBS who tested positive for one or more food sensitivities via the IgG assay were assigned to either an antibody-guided elimination diet or a sham diet for 8 weeks. The experimental group excluded foods identified as triggers by the IgG assay, while the sham group followed a diet excluding random foods.
The primary outcome was achieving a clinically meaningful reduction in abdominal pain intensity (≥30%) for at least 2 of the final 4 weeks of treatment. Results showed that the experimental group had significantly higher response rates compared to the sham group (59.6% vs 42.1%; P = .02). Subgroup analysis revealed stronger improvements among individuals with constipation-predominant IBS (IBS-C) and mixed-type IBS (IBS-M).
These findings suggest that the IgG-guided elimination diet may serve as a safe, non-pharmacologic treatment option for IBS, particularly for patients unresponsive to conventional therapies. However, larger trials are needed to confirm these results, refine dietary protocols, and assess long-term efficacy and adherence.
Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...
Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...
Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...
Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...
Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...
Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.